explore -WSS

explore

author：knowledge 2025-10-03 01:05:48 - browse：39

Perrigo Opill press photo – pharma coverage from STAT — Opill, the first over-the-counter birth control pill, is on its way to U.S. stores. Perrigo via AP

WASHINGTON — The first over-the-counter birth control pill will be available in U.S. stores later this month, allowing American women and teens to purchase contraceptive medication as easily as they buy aspirin.

Manufacturer Perrigo said Monday it has begun shipping the medication, Opill, to major retailers and pharmacies. A one-month supply will cost about $20 and a three-month supply will cost around $50, according to the company’s suggested retail price. It will also be sold online.

The launch has been closely watched since last July, when the Food and Drug Administration said the once-a-day Opill could be sold without a prescription. Ireland-based Perrigo noted there will be no age restrictions on sales, similar to other over-the-counter medications.

Opill is an older class of contraceptive, sometimes called minipills, that contain a single synthetic hormone, progestin, and generally carry fewer side effects than more popular combination estrogen and progestin pills.

Newsletters

Sign up for Morning Rounds

Understand how science, health policy, and medicine shape the world every day

Please enter a valid email address. Privacy Policy

The launch gives U.S. women another birth control option amid the legal and political battles over reproductive health, including the reversal of Roe v. Wade, which has upended abortion access across the U.S. Opill’s approval is unrelated to the ongoing court battles over the abortion pill mifepristone. And anti-abortion groups have generally emphasized that they do not oppose contraceptives to prevent pregnancies.

Birth control pills are available without a prescription across much of South America, Asia, and Africa.

The drug’s approval came despite some concerns by FDA scientists about the company’s results, including whether women with certain medical conditions would understand that they shouldn’t take the drug.

Dr. Verda Hicks, president of the American College of Obstetricians and Gynecologists, in a statement, said studies have shown that patients, including adolescents, can effectively screen themselves to use the pills.

— Matthew Perrone

Previous article： Drug repurposing or repositioning? The language matters
Next article： 'Make People Better': The CRISPR babies story you probably don't know

hotspot

WSS

Chronically ill young patients struggle to find fertility info

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

The (many) problems with a new study criticizing cancer screening

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

explore

explore

Sign up for Morning Rounds

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Videos point to link between seizures and unexplained toddler deaths

The high cost of giving birth even with insurance

The biotech scorecard for Q1: 17 stock

Cancer drug shortages should be causing more outrage

A single drug, study failures leave Anavex with nothing but cash

George Santos makes 1st court appearance after pleading not guilty to 13 counts

ALS advocates say criticism of new drugs misses bigger picture

What does generative AI mean for health care? We asked experts

The (many) problems with a new study criticizing cancer screening

leisure time

J&J to buy cancer drug developer Ambrx Biopharma

The (many) problems with a new study criticizing cancer screening

The (many) problems with a new study criticizing cancer screening

Chronically ill young patients struggle to find fertility info

JPM: CVS says Medicare Advantage patients are impacting profits

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Wikipedia

hotspot

entertainment

knowledge